Business Description
Shanghai RAAS Blood Products Co Ltd
NAICS : 325414
ISIN : CNE100000C31
Share Class Description:
SZSE:002252: Class ACompare
Compare
Traded in other countries / regions
002252.China IPO Date
2008-06-23Description
Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has high comprehensive utilization of plasma raw material and a range of products with different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The company's products include albumin, coagulation factors, and others.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2429.49 | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | 21159.37 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 14.58 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 40.2 | |||||
3-Year EBITDA Growth Rate | 11.5 | |||||
3-Year EPS without NRI Growth Rate | 8.7 | |||||
3-Year FCF Growth Rate | 24.1 | |||||
3-Year Book Growth Rate | 6.2 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.43 | |||||
9-Day RSI | 66.67 | |||||
14-Day RSI | 65.04 | |||||
6-1 Month Momentum % | -7.07 | |||||
12-1 Month Momentum % | -5.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.05 | |||||
Quick Ratio | 2.51 | |||||
Cash Ratio | 2.16 | |||||
Days Inventory | 255.64 | |||||
Days Sales Outstanding | 26.81 | |||||
Days Payable | 116.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.38 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | 44.2 | |||||
Forward Dividend Yield % | 0.38 | |||||
5-Year Yield-on-Cost % | 0.38 | |||||
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 39.73 | |||||
Operating Margin % | 28.99 | |||||
Net Margin % | 22.84 | |||||
FCF Margin % | 18.4 | |||||
ROE % | 6.07 | |||||
ROA % | 5.69 | |||||
ROIC % | 7.28 | |||||
ROC (Joel Greenblatt) % | 67.52 | |||||
ROCE % | 7.56 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 28.45 | |||||
PE Ratio without NRI | 27.46 | |||||
Shiller PE Ratio | 41.47 | |||||
Price-to-Owner-Earnings | 33.39 | |||||
PS Ratio | 6.5 | |||||
PB Ratio | 1.72 | |||||
Price-to-Tangible-Book | 2.08 | |||||
Price-to-Free-Cash-Flow | 35.5 | |||||
Price-to-Operating-Cash-Flow | 26.52 | |||||
EV-to-EBIT | 21.17 | |||||
EV-to-EBITDA | 21.17 | |||||
EV-to-Revenue | 6.03 | |||||
EV-to-FCF | 32.13 | |||||
Price-to-Projected-FCF | 1.29 | |||||
Price-to-Median-PS-Value | 0.32 | |||||
Price-to-Graham-Number | 1.6 | |||||
Price-to-Net-Current-Asset-Value | 7.58 | |||||
Price-to-Net-Cash | 20.21 | |||||
Earnings Yield (Greenblatt) % | 4.72 | |||||
FCF Yield % | 2.8 | |||||
Forward Rate of Return (Yacktman) % | 20.56 |